CEO & Co-Founder
Brings vast experience in project management and R&D in a wide range of chemistry based medical devices.
Holds a B.Sc and M.Sc in chemistry from the Hebrew University, PhD from Ben-Gurion University in Israel and conducted his post-doctorate at the University of California, Berkeley, USA.
Biotech Senior Manager with Experienced in building maintaining QA/Compliance in Pharma. US market expert & Strategic thinker.
Production and Lab Manager
Experienced QC manager in the pharmaceuticals industry and GMP analysis and production. Holds B.Sc in chemistry from the Technion Institute.
Experienced in planning and managing global clinical trials in medical devices and pharmaceuticals since 2007, and served as clinical trials manager, director, project manager and independent consultant in numerous Israeli companies.
Manages the finances of NGT portfolio companies with strong, proven leadership.
Involved in fund-raising, negotiations and complex transactions.
Chairman of the Board
CEO and Managing Partner of NGT3 VC. Led the establishment of and investment in more than 50 companies such as Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), Corindus (sold to Siemens Healthcare for $1.1B), and many others.
As an inventor of a dozen approved products Avi brings vast experience in pharmaceutical development and innovation.
Holds a PhD in chemistry and undergraduate degrees in chemistry, pharmaceutics, and law.
Brings experience as a seasoned entrepreneur with more than ten years in the Israeli Medtech/Pharma industry.
Previously founded and served as CEO of Vensica Therapeutics, where Avner led large, strategic and successful funding rounds.
Has a background in premedical studies and molecular biology (B.Sc, Yale) and BioMedical Engineering (M.Sc. Technion).
Head of Sharett institute of Oncology.
Specialist in ENT, Medical and Radiation Oncology.